Aurobindo Pharma Limited (AUROPHARMA)

Name: Aurobindo Pharma Limited (AUROPHARMA) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas.

Cifras clave

Capitalización bursátil: ₹998 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹333.8B
Beneficio neto: ₹35.0B
Margen bruto: 57.1%
Margen neto: 10.5%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	₹333.8B	₹313.8B	₹287.0B	₹246.2B
Beneficio bruto	₹190.6B	₹176.4B	₹154.7B	₹127.2B
Ingresos operativos (EBIT)	₹51.9B	₹50.5B	₹44.4B	₹25.4B
Ingresos netos	₹35.0B	₹34.9B	₹31.7B	₹19.3B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de AUROPHARMA. /companies/us/AUROPHARMA

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.